stockrow
Saturday 7 November 2026
Export RZLT’s income statement to Excel — free account
Rezolute, Inc.
RZLT Healthcare Biotechnology
- EPS
- +23.1%
- Free cash flow
- +40.2%
Quarter to June 2026, against a year earlier
3.85
0.21
+5.77%
Follow RZLT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | 2 | 54 | 156 | +762.1% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.0 pt | ||||||
| EBT | (20) | (30) | (30) | (20) | (21) | (41) | (52) | (68) | (74) | (78) | +16.1% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (20) | (30) | (30) | (20) | (21) | (41) | (52) | (68) | (74) | (78) | +16.1% | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (28.50) | (26.27) | (18.41) | (3.54) | (2.72) | (2.26) | (1.01) | (1.33) | (0.98) | (0.75) | (33.2%) | ||||||
| Cash flow | (16.12) | (12.68) | (8.61) | (4.20) | (2.66) | (2.18) | (0.87) | (1.11) | (0.91) | (0.62) | (30.3%) | ||||||
| Capex | (0.49) | 1.39 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (16.61) | (11.29) | (8.48) | (4.20) | (2.66) | (2.18) | (0.87) | (1.11) | (0.91) | (0.62) | (30.6%) | ||||||
| Book value | 10.33 | (3.56) | 0.99 | 1.28 | 3.40 | 8.21 | 2.27 | 2.35 | 2.13 | 0.97 | (23.1%) | ||||||
| Shares, m | 1 | 1 | 2 | 6 | 8 | 18 | 51 | 51 | 76 | 104 | +71.1% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | (13) | (14) | (15) | (24) | (20) | (40) | (44) | (57) | (69) | (65) | +19.2% | |||||
| Capex | 0 | 2 | 0 | — | — | — | 0 | — | — | — | (15.1%) | ||||||
| Free cash flow | (14) | (13) | (15) | (24) | (20) | (40) | (45) | (57) | (69) | (65) | +18.8% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 3 | (4) | 4 | 7 | 40 | 150 | 100 | 119 | 159 | 99 | +46.7% | |||||
| Net debt | (4) | (2) | (12) | (10) | (27) | (150) | (102) | (127) | (168) | (108) | +42.4% | ||||||
| Shareholders’ equity | 9 | (4) | 2 | 7 | 26 | 149 | 116 | 121 | 162 | 101 | +31.6% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (219.99) | (454.80) | (443.50) | (175.16) | (78.03) | (42.11) | (37.51) | (53.39) | (48.28) | (53.82) | +166.2 pt | |||||
| ROIC | (314.30) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (245.12) | 0.00 | 0.00 | 0.00 | +314.3 pt | ||||||
| ROE | (273.79) | (1,307.73) | 2,962.34 | (446.05) | (124.92) | (46.77) | (38.99) | (57.73) | (52.56) | (59.04) | +214.8 pt | ||||||
| People | |||||||||||||||||
| People | Employees | 50 | 21 | 20 | 23 | 26 | 42 | 51 | 59 | 71 | 58 | +1.7% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Rezolute, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics, Inc. | $362.9M | — (loss-making) | — (loss-making) | −24.59% (below 0%: shrinking) | n/m | +17.88% (above 0%: growing) | 100.00% | (290.46%) | Compare |
| ZURA Zura Bio Limited | $358.3M | — (loss-making) | — | — | n/m | −26.22% (below 0%: shrinking) | — | 0.00% | Compare |
| TRXB TRex Bio Inc. | $356.5M | — | — | — | — | — | — | — | Compare |
| AVTX Avalo Therapeutics, Inc. | $355.6M | — (loss-making) | — (loss-making) | −70.14% (below 0%: shrinking) | n/m | +75.70% (above 0%: growing) | 55.73% | 0.00% | Compare |
| RZLT Rezolute, Inc. | $352.1M | — (loss-making) | — | — | n/m | +40.23% (above 0%: growing) | 0.00% | 0.00% | |
| CTNM Contineum Therapeutics, Inc. | $345.9M | — (loss-making) | — | — | n/m | +10.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MPLT MapLight Therapeutics, Inc. | $345.7M | — (loss-making) | — | — | n/m | −31.91% (below 0%: shrinking) | — | 0.00% | Compare |
| AGMB AgomAb Therapeutics NV | $343.3M | — | — | — | — | — | — | — | Compare |
| SRZN Surrozen, Inc. | $340.9M | — (loss-making) | — (loss-making) | +408.65% (above 0%: growing) | n/m | −21.25% (below 0%: shrinking) | 100.00% | (207.40%) | Compare |
| Median of peers | $350.7M | — | — | −24.59% | — | −5.60% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 21 October 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2026 | 5.71m | 4.09m | 263.00 |
| 2025 | 2.85m | 2.10m | 225.00 |
| 2024 | 1.19m | 4.96m | 217.00 |
Ownership
Directors and executive officers, together
15.05%
Entities associated with Federated Hermes, Inc.
16.49%
RA Capital Management, L.P.
9.76%
Young-Jin Kim
8.95%
Handok, Inc.
8.71%
BlackRock
7.98%
Opaleye Management Inc.
6.51%
Dellora Investments Master Fund, L.P.
5.92%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement